Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Yan

Showing results (561-570 of 630) with videos related to

Pageof 63
Sort By:
European Heart Journal|September 12, 2018
Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarctionMarlous Hall, Owen J Bebb, Tatandashe B Dondo, et al.
European Radiology|January 7, 2022
Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumabFlora Huang, Christine Brezden-Masley, Kelvin K W Chan, et al.
Metabolism Open|August 20, 2020
Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysisVinay Garg, Subodh Verma, Kim A Connelly, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|February 10, 2026
[Strategies for aortic arch branch reconstruction during thoracic endovascular aortic repair]L T Yan, H Liu, L W Zou, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 29, 2023
Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodelingEhab Bakbak, Subodh Verma, Aishwarya Krishnaraj, et al.
Journal of Cardiology|December 3, 2021
Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registryJuan J Russo, Andrew T Yan, Stuart J Pocock, et al.
The International Journal of Cardiovascular Imaging|November 4, 2018
Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal studyInna Y Gong, Geraldine Ong, Christine Brezden-Masley, et al.
Radiology. Cardiothoracic Imaging|November 15, 2021
Right Ventricular Mass 12 Years after Osteosarcoma: Multimodality Imaging with Pathologic CorrelationBadr Bannan, Huda S Ismail, Faisal M Alabdulkarim, et al.
Nephrology (Carlton, Vic.)|May 23, 2018
Left ventricular strain analysis using cardiac magnetic resonance imaging in patients undergoing in-centre nocturnal haemodialysisJann P Ong, Ron Wald, Marc B Goldstein, et al.
Cardiovascular Endocrinology & Metabolism|June 29, 2026
Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trialWei-Siang Chen, Ning-I Yang, Subodh Verma, et al.
Pageof 63

Showing results (561-570 of 630) with videos related to

Sort By:
Pageof 63
European Heart Journal|September 12, 2018
Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarctionMarlous Hall, Owen J Bebb, Tatandashe B Dondo, et al.
European Radiology|January 7, 2022
Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumabFlora Huang, Christine Brezden-Masley, Kelvin K W Chan, et al.
Metabolism Open|August 20, 2020
Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysisVinay Garg, Subodh Verma, Kim A Connelly, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|February 10, 2026
[Strategies for aortic arch branch reconstruction during thoracic endovascular aortic repair]L T Yan, H Liu, L W Zou, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 29, 2023
Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodelingEhab Bakbak, Subodh Verma, Aishwarya Krishnaraj, et al.
Journal of Cardiology|December 3, 2021
Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registryJuan J Russo, Andrew T Yan, Stuart J Pocock, et al.
The International Journal of Cardiovascular Imaging|November 4, 2018
Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal studyInna Y Gong, Geraldine Ong, Christine Brezden-Masley, et al.
Radiology. Cardiothoracic Imaging|November 15, 2021
Right Ventricular Mass 12 Years after Osteosarcoma: Multimodality Imaging with Pathologic CorrelationBadr Bannan, Huda S Ismail, Faisal M Alabdulkarim, et al.
Nephrology (Carlton, Vic.)|May 23, 2018
Left ventricular strain analysis using cardiac magnetic resonance imaging in patients undergoing in-centre nocturnal haemodialysisJann P Ong, Ron Wald, Marc B Goldstein, et al.
Cardiovascular Endocrinology & Metabolism|June 29, 2026
Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trialWei-Siang Chen, Ning-I Yang, Subodh Verma, et al.
Pageof 63